• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

First trial of the HIV-1 vaccine in Africa: Ugandan experience.

作者信息

Mugerwa Roy D, Kaleebu Pontiano, Mugyenyi Peter, Katongole-Mbidde Edward, Hom David L, Byaruhanga Rose, Salata Robert A, Ellner Jerrold J

机构信息

Department of Medicine, Makerere University Medical School, Kampala, Uganda.

出版信息

BMJ. 2002 Jan 26;324(7331):226-9. doi: 10.1136/bmj.324.7331.226.

DOI:10.1136/bmj.324.7331.226
PMID:11809648
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1122137/
Abstract
摘要

相似文献

1
First trial of the HIV-1 vaccine in Africa: Ugandan experience.HIV-1疫苗在非洲的首次试验：乌干达的经验。
BMJ. 2002 Jan 26;324(7331):226-9. doi: 10.1136/bmj.324.7331.226.
2
Uganda pioneers ALVAC -- and informed consent. Vaccine trials.
AIDS Anal Afr. 1997 Feb;7(1):2-3.
3
HIV vaccine trials for Uganda?
Lancet. 1994 Apr 9;343(8902):910. doi: 10.1016/s0140-6736(94)90024-8.
4
Testing therapies less effective than the best current standard: ethical beliefs in an international sample of researchers.测试比当前最佳标准疗效更差的疗法：国际研究人员样本中的伦理观念
Am J Bioeth. 2003 Spring;3(2):W11. doi: 10.1162/152651603322874898.
5
Uganda gets set for vaccine trials, but the ethical debate continues.乌干达准备进行疫苗试验，但伦理辩论仍在继续。
AIDS Anal Afr. 1997 Apr;7(2):1.
6
HIV vaccines: the Uganda experience.艾滋病毒疫苗：乌干达的经验
Vaccine. 2002 May 6;20(15):1905-8. doi: 10.1016/s0264-410x(02)00064-6.
7
Uganda will provide HIV vaccine subjects in return for services. Conference coverage (NCVDG).乌干达将提供艾滋病毒疫苗试验对象以换取服务。会议报道（国家病毒性疾病控制司）
AIDS Wkly Plus. 1996 Mar 4:10-1.
8
The challenges of HIV vaccine development and testing.HIV疫苗研发与测试的挑战。
Best Pract Res Clin Obstet Gynaecol. 2005 Apr;19(2):277-91. doi: 10.1016/j.bpobgyn.2004.11.001.
9
Provision of treatment in HIV-1 vaccine trials in developing countries.在发展中国家开展的HIV-1疫苗试验中的治疗提供情况。
Lancet. 2003 Sep 20;362(9388):993-4. doi: 10.1016/S0140-6736(03)14372-3.
10
Thorny issues in the ethics of AIDS vaccine trials.艾滋病疫苗试验伦理中的棘手问题。
Lancet. 2003 Sep 20;362(9388):992. doi: 10.1016/S0140-6736(03)14371-1.

引用本文的文献

1
Advancing Sustainable HIV Services Through Integration in Primary Healthcare in Sub-Saharan Africa: A Perspective on Practical Recommendations.通过撒哈拉以南非洲地区初级卫生保健整合推进可持续的艾滋病毒服务：关于实际建议的观点
Healthcare (Basel). 2025 Jan 19;13(2):192. doi: 10.3390/healthcare13020192.
2
Medical experimentation on prisoners (part 6): Situation in Africa, Middle East and part of the Arab world (Tunisia in particular).对囚犯进行医学实验（第6部分）：非洲、中东及部分阿拉伯世界（特别是突尼斯）的情况。
Tunis Med. 2022;100(12):819-823.
3
Developing capacity for implementation and evaluation of vaccine trials in Uganda: Perspective of the Makerere University Walter Reed Project.在乌干达开展疫苗试验的实施和评估能力建设：马凯雷雷大学沃尔特·里德项目的观点。
Afr Health Sci. 2022 Aug;22(Spec Issue):34-41. doi: 10.4314/ahs.v22i2.6S.
4
Young at risk-people in Maputo City, Mozambique, present a high willingness to participate in HIV trials: Results from an HIV vaccine preparedness cohort study.莫桑比克马普托市的高危年轻人表现出高度参与 HIV 试验的意愿：来自 HIV 疫苗准备队列研究的结果。
PLoS One. 2021 Dec 2;16(12):e0260126. doi: 10.1371/journal.pone.0260126. eCollection 2021.
5
Sociodemographic factors associated with acceptance of COVID-19 vaccine and clinical trials in Uganda: a cross-sectional study in western Uganda.乌干达西部一项横断面研究：与 COVID-19 疫苗和临床试验接受度相关的社会人口学因素。
BMC Public Health. 2021 Jun 10;21(1):1106. doi: 10.1186/s12889-021-11197-7.
6
COVID-19 preparedness: capacity to manufacture vaccines, therapeutics and diagnostics in sub-Saharan Africa.COVID-19 应对准备：撒哈拉以南非洲地区疫苗、疗法和诊断试剂的生产能力。
Global Health. 2021 Mar 3;17(1):24. doi: 10.1186/s12992-021-00668-6.
7
Major Scientific Hurdles in HIV Vaccine Development: Historical Perspective and Future Directions.艾滋病疫苗研发的主要科学障碍：历史回顾与未来方向。
Front Immunol. 2020 Oct 28;11:590780. doi: 10.3389/fimmu.2020.590780. eCollection 2020.
8
Perception of potential harm and benefits of HIV vaccine trial participation: A qualitative study from urban Tanzania.艾滋病毒疫苗试验参与的潜在危害和益处感知：来自坦桑尼亚城市的定性研究。
PLoS One. 2019 Nov 8;14(11):e0224831. doi: 10.1371/journal.pone.0224831. eCollection 2019.
9
The Medical Research Council (UK)/Uganda Virus Research Institute Uganda Research Unit on AIDS--'25 years of research through partnerships'.英国医学研究理事会/乌干达病毒研究所乌干达艾滋病研究室——“通过伙伴关系开展25年研究”
Trop Med Int Health. 2015 Feb;20(2):E1-10. doi: 10.1111/tmi.12415. Epub 2014 Oct 29.
10
Balancing collective responsibility, individual opportunities and risks: a qualitative study on how police officers reason around volunteering in an HIV vaccine trial in Dar es Salaam, Tanzania.平衡集体责任、个人机会和风险：坦桑尼亚达累斯萨拉姆一项关于警察在 HIV 疫苗试验中自愿参与的理由的定性研究。
BMC Public Health. 2010 May 28;10:292. doi: 10.1186/1471-2458-10-292.

本文引用的文献

1
Developing AIDS vaccine trials educational programs in Uganda.在乌干达开展艾滋病疫苗试验教育项目。
J Acquir Immune Defic Syndr. 2001 Feb 1;26(2):176-81. doi: 10.1097/00042560-200102010-00012.
2
Human immunodeficiency virus vaccine development in developing countries: are efficacy trials feasible?发展中国家的人类免疫缺陷病毒疫苗研发：疗效试验可行吗？
J Hum Virol. 2000 Jul-Aug;3(4):193-214.
3
Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how?加速HIV-1疫苗的研发及未来可得性：为何、何时、何地以及如何？
Lancet. 2000 Jun 10;355(9220):2061-6. doi: 10.1016/S0140-6736(00)02360-6.
4
Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida.在低感染HIV风险的健康志愿者中，表达1型HIV gp120 MN MN tm/gag/蛋白酶LAI（ALVAC-HIV，vCP205）的重组金丝雀痘病毒活疫苗，随后接种p24E-V3 MN合成肽（CLTB-36）的安全性和免疫原性。AGIS集团和法国国家艾滋病研究机构。
AIDS Res Hum Retroviruses. 1999 May 1;15(7):633-45. doi: 10.1089/088922299310935.
5
HIV vaccine development for the world: an idea whose time has come?
AIDS Res Hum Retroviruses. 1998 Oct;14 Suppl 3:S191-6.
6
Bioethics and local circumstances.
Science. 1998 Jan 9;279(5348):155. doi: 10.1126/science.279.5348.155a.
7
HIV-1 risk and vaccine acceptability in the Ugandan military.
J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Aug 15;15(5):375-80. doi: 10.1097/00042560-199708150-00008.
8
Ethical, behavioral, and social aspects of HIV vaccine trials in developing countries.发展中国家艾滋病毒疫苗试验的伦理、行为和社会方面。
JAMA. 1994 Jan 26;271(4):295-301.
9
Behavioral research contributions to planning and conducting HIV vaccine efficacy studies.行为研究对规划和开展HIV疫苗效力研究的贡献。
AIDS Res Hum Retroviruses. 1994;10 Suppl 2:S277-80.
10
The safety and use of canarypox vectored vaccines.金丝雀痘病毒载体疫苗的安全性及应用
Dev Biol Stand. 1995;84:165-70.